Clinical Studies Search

Protocol Summary

Protocol No.
Prinicipal Investigator
Belani, Chandra
Age Group
Characterization of Oncogenic Mutations in Patients with Advanced Squamous Cell Lung Cancer
To determine the frequency of oncogenic mutation/amplification in tumors from patients with advanced lung squamous cell carcinoma (SCC). The mutations or expression of interest include those seen in DDR2 mutation, PIK3CA mutation, PTEN mutation and loss, expression of Desmocollin-3, and amplification of FGFR1 and PIK3CA.
To correlate the presence of the oncogenic mutation/amplification/expression with clinical outcome. The clinical features associated with these mutations/ amplifications are not well characterized as the testing for these abnormalities has not been done in the current clinical setting. As some of these mutations/amplifications/expression are drugable, the ultimate goal will be to develop effective therapies with better understanding of the biology of lung cancer.
To enumerate circulating tumor cells from the same patients with advanced lung SCC and correlate with clinical outcome and detect the presence of the oncogenic mutations/amplification/expression as outlined above. The tumor cell heterogeneity in the CTC population will be examined and compared with that seen in primary tumor samples
To evaluate the tumor from these patients with advanced lung SCC for additional gene mutations of interest seen by NEXT GENERATION SEQUENCING (NGS)
Applicable Disease Sites
Participating Institutions
Hershey Medical Center